This workshop will focus on the need for standards to support the burgeoning biotech and pharma industries developing clinical applications that target the human microbiome. Informed regulatory decision making requires an understanding of the analytical performance of the assays being used to verify the identity, purity, potency and stability of these biomanufactured Live Biotherapeutic Products (LBPs). Additionally, clinical microbiome laboratory tests must be validated before being used for donor screening, monitoring engraftment or evaluating other changes that occur in a patient’s microbiome before, during and after therapeutic intervention. For more information, please visit https://go.usa.gov/xywhM
Agenda (PDF)
Last day to register is September 03, 2019.
Register
For more information, please contact NISTmicrobiome@nist.gov
No comments:
Post a Comment